lily tirzepatide https://investor.lilly.com/news-releases/news-release-details/zepbound- tirzepatide-most-prescribed-weight-management “Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for Zepbound Eli Lilly's tirzepatide is off

Preclinical Results Highlight Competitive Potential Preclinical data released by SureNano Science suggest that GEP-44 may offer meaningful differentiation compared with earlier-generation GLP therapies, positioning the company for meaningful upside as it progresses through its development phases of the FDA approval pathway

Impressive Weight Loss Outcomes: Patients have reported an average weight loss of 15% within the first month of treatment, backed by a money-back guarantee if certain conditions are not met

Clark called it the incredible watershed case. William Soliman, PhD, founder and CEO of the Accreditation Council for Medical Affairs and former Merck sales rep, saw the pressure firsthand

Although differences in the rates at which men and women develop Alzheimer's or other dementias do not appear to be large or consistent, the reasons men and women develop dementia may vary

Neither issue is a deal-breaker, but both are worth knowing about before signing up